Pathological complete response of hepatocellular carcinoma confirmed by conversion hepatectomy following atezolizumab plus bevacizumab therapy: a case report and literature review
Clinical Journal of Gastroenterology,
Journal Year:
2023,
Volume and Issue:
17(2), P. 292 - 299
Published: Dec. 10, 2023
Abstract
The
combination
regimen
of
atezolizumab
plus
bevacizumab
(Atezo/Bev)
is
currently
used
as
first-line
treatment
in
patients
with
unresectable
hepatocellular
carcinoma.
Herein,
we
report
a
rare
case
curative
hepatic
resection
performed
conversion
surgery
patient
intermediate-stage
carcinoma
following
preoperative
Atezo/Bev
therapy.
After
five
cycles
therapy,
followed
by
four
monotherapy,
the
tumor
marker
levels
decreased
to
baseline
and
22
small
daughter
nodules
disappeared,
leaving
only
primary
tumor.
Therefore,
surgery,
postoperative
histopathology
confirmed
complete
necrosis.
No
cancer
recurrence
has
been
observed
until
5-month
follow-up,
remains
drug
free.
Consistent
findings
this
case,
review
previously
reported
cases
revealed
that
successful
neoadjuvant
therapy
was
associated
intra-tumoral
bleeding,
immune-related
adverse
events,
normalization
levels.
Language: Английский
Liver Resection and Transplantation in the Era of Checkpoint Inhibitors
JHEP Reports,
Journal Year:
2024,
Volume and Issue:
6(11), P. 101181 - 101181
Published: Aug. 7, 2024
Immune
checkpoint
inhibitors
(ICIs)
have
revolutionised
the
treatment
landscape
for
advanced
hepatocellular
carcinoma
(HCC).
The
combination
of
atezolizumab
and
bevacizumab
has
demonstrated
efficacy,
establishing
a
new
standard
care
HCC.
Neoadjuvant
studies
shown
promising
results
with
high
response
rates,
increasing
research
into
ICIs'
role.
In
peri-operative
setting,
in
addition
to
adjuvant
neo-adjuvant
therapies,
strategies
"downstaging"
"bridging"
patients
liver
transplantation
(LT)
are
being
investigated,
broadening
eligible
candidate
pool.
Furthermore,
therapeutic
advances
reshaped
conversion
hepatic
resection,
emerging
evidence
indicating
role
immunotherapy
at
risk
postoperative
recurrence.
LT,
concerns
arisen
over
potential
conflict
between
immunosuppression
needs
immune-enhancing
effects
ICIs,
reports
severe
rejection.
However,
liver-specific
factors
may
lessen
rejection
risks,
prompting
exploration
safety
pre-transplant
ICI
administration.
Moreover,
ongoing
trials
must
prioritise
patient
selection
vigilant
management
protocols.
Despite
remarkable
progress
immunotherapy,
intricate
molecular
interactions
within
tumour
microenvironment
their
implications
on
oncogenic
pathways
remain
incompletely
understood.
This
highlights
need
specialised
expertise
effectively
integrate
surgical
Key
challenges
include
ensuring
safety,
optimising
oncological
outcomes,
managing
graft
transplant
recipients,
refining
criteria.
this
review,
we
aim
provide
comprehensive
overview
evolving
HCC,
discussing
rationale
its
application
both
pre-
post-surgical
contexts,
leveraging
current
clinical
experience,
identifying
limitations,
envisioning
future
applications.
By
integrating
existing
knowledge
highlighting
areas
further
investigation,
review
seeks
inform
practice
guide
endeavours.
Language: Английский
A patient alive without disease 32 months after conversion surgery following lenvatinib treatment for hepatocellular carcinoma with a tumor thrombus originating in the middle hepatic vein and reaching the right atrium via the suprahepatic vena cava: a case report
Yu Gyoda,
No information about this author
Hirofumi Ichida,
No information about this author
Fumihiro Kawano
No information about this author
et al.
Clinical Journal of Gastroenterology,
Journal Year:
2024,
Volume and Issue:
17(2), P. 311 - 318
Published: Jan. 26, 2024
Language: Английский
Robot-assisted extended rectal anterior resection for peritoneal dissemination of hepatocellular carcinoma invading rectum after atezolizumab plus bevacizumab combined therapy
International Cancer Conference Journal,
Journal Year:
2024,
Volume and Issue:
13(4), P. 336 - 341
Published: June 5, 2024
Language: Английский
Successful radical surgery for lymph node metastasis in a patient with hepatocellular carcinoma following atezolizumab plus bevacizumab combination therapy: a case report and literature review
Ken Sato,
No information about this author
Takehiro Shimizu,
No information about this author
Akira Watanabe
No information about this author
et al.
Clinical Journal of Gastroenterology,
Journal Year:
2024,
Volume and Issue:
17(6), P. 1067 - 1074
Published: Aug. 20, 2024
Language: Английский
A Case of Advanced Hepatocellular Carcinoma with Multiple Intrahepatic Metastases and Peritoneal Dissemination Treated using Atezolizumab plus Bevacizumab Combination Therapy, Resulted in Pathological Complete Response, with Concomitant Endoscopic Therapies for Early Gastric and Colorectal Cancers
Itsumi Ka,
No information about this author
Akinori Nakata,
No information about this author
Shotaro Ishii
No information about this author
et al.
Kanzo,
Journal Year:
2024,
Volume and Issue:
65(9), P. 440 - 448
Published: Sept. 1, 2024
Language: Английский